–
The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibodies to treat COVID-19 for certain patients. Monoclonal antibodies may be available through expanded access programs to treat COVID-19 for immunocompromised patients. However, the efficacy of use for immunocompromised patients is unclear.
During this COCA Call, presenters will discuss the FDA’s role in issuing EUAs for certain monoclonal antibodies, options for compassionate use, the process for ordering and distributing monoclonal antibodies, and current data on using monoclonal antibodies for both non-hospitalized and immunocompromised patients. Presenters will also cover preventing, diagnosing, and treating COVID-19 in immunocompromised patients, including the role of monoclonal antibodies, serologic testing, and potential third dose of COVID-19 vaccinations.
Webinar Link: https://www.zoomgov.com/j/1612254638?pwd=SmNaNlJEUWt3YWdBMGtNRjhxRlZ1UT09external icon
Passcode: 980771
Dial In:
US: +1 669 254 5252
or +1 646 828 7666
or +1 669 216 1590
or +1 551 285 1373
One-tap mobile:
US: +16692545252,,1612254638#,,,,*980771# or +16468287666,,1612254638#,,,,*980771#
Webinar ID: 161 225 4638
Elliot Raizes, MD
Task Force Lead
Health Services and Worker Safety Task Force
COVID-19 Response
Centers for Disease Control and Prevention
John Farley, MD, MPH
Director, Office of Infectious Diseases
Center for Drug Evaluation and Research
Office of New Drugs
U.S. Food and Drug Administration
Colin Shepard, MD
CDC Liaison to the Assistant Secretary for Preparedness and Response (ASPR)
Center for Preparedness and Response
Centers for Disease Control and Prevention
Rajesh Gandhi, MD
Director, HIV Clinical Services and Education, Massachusetts General Hospital
Professor of Medicine, Harvard Medical School
Adi Gundlapalli, MD, PhD, MS
Chief Public Health Informatics Officer
Deputy Director, Public Health Science and Surveillance
Public Health Informatics Office
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention
–
Every other Thursday at 4:00 PM-5:30 PM Eastern
A link to RSVP is provided shortly before each call and will be added here ASAP.
Note: You must RSVP to join the call. Upon successful registration, you will receive a confirmation email with dial-in instructions.
–
National Congress of American Indians (NCAI) and NAFOA will host a webinar featuring speakers discussing the new Tribal Government State Small Business Credit Initiative (SSBCI) with speakers from the Department of the Treasury (Treasury).
The webinar will provide information about the SSBCI program, how to file a Notice of Intent, and Treasury will answer participant questions about the program/application process.
Included as a provision in the American Rescue Plan Act, SSBCI funds tribal, state, and territory small business and support programs. SSBCI has at least $500 million allocated for Tribal Nations. To access this funding, Tribal Nations must provide Treasury with a Notice of Intent by August 16, 2021.
Stakeholders are invited to join Assistant Secretary for Health for the U.S. Department of Health and Human Services (HHS), Rachel L. Levine, M.D., Acting FDA Commissioner, Janet Woodcock, M.D., and Peter Marks, M.D., Ph.D., Director, FDA Center for Biologics Evaluation and Research, to discuss vaccine updates for younger children and adolescents.
One tap mobile: | US: +16692545252,,1607308686#,,,,*470339# or +16468287666,,1607308686#,,,,*470339# |
Meeting URL: | https://fda.zoomgov.com/j/1607308686?pwd=eHBJWGZWRjYwZWkrN0lFams1akIrZz09 |
Meeting ID: | 160 730 8686 |
Passcode: | 0N!Nns |
Join by Telephone | |
For higher quality, dial a number based on your current location. | |
Dial: | US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590 or 833 568 8864 (Toll Free) |
Meeting ID: | 160 730 8686 |
Passcode: | 470339 |